implantologie
C ONCLUSIONS
osteonecrosis of the femoral head: comparison of extracorporeal shock waves with
core decompression and bone-grafting. J Bone Joint Surg Am. 87 (2005), 2380-
Le traitement par ondes de chocs extracorporelles des ostéoné-
2387.
croses des maxillaires pourrait être un traitement adjuvant aux trai-
16 d’Agostino C, Romeo P, Amelio E, Sansone V. Effectiveness of ESWT in the treat-
tements chirurgicaux. Bien entendu, d’autres études doivent confir-
ment of Kienbock’s disease. Ultrasound in Med & Biol. Vol. 37 (n° 9) (2011), 1452 –
mer l’efficacité de ce type de prise en charge et surtout affiner le
1457.
protocole thérapeutique.
17 Wang, CJ. An overview of shock wave therapy in musculoskeletal disorders.
Chang Gung Med. 26v (2003), 220 - 232.
Le principal effet que nous recherchions à l’origine, était une analgésie. L’hypothèse avancée était que la douleur était d’abord une
18 Ogden JA, Tóth-Kischkat A, Schultheiss R. Principles of shock wave therapy. Clin
douleur ischémique. Il semble que cette technique puisse apporter
Orthop. 2001;387:8–17.
un effet analgésique rapide et durable par son effet revascularisant
19 Siebert W, Buch M, editor. Extracorporeal shock waves in orthopaedics. Berlin,
en même temps qu’une amélioration de la cicatrisation osseuse des
Springer Verlag; 1997. pp. 1–245.
lésions nécrotiques.
20 Mariotto S, de Prati AC, Cavalieri E, Amelio E, Marlinghaus E, Suzuki H.
Extracorporeal shock wave therapy in inflammatory diseases: molecular mechanism
that triggers anti-inflammatory action. Curr Med Chem. 2009;16(19):2366-72.
21 Cooke JP, Losordo DW. Nitric Oxide and Angiogenesis. Circulation 105 (2002),
R ÉFÉRENCES
pp. 2133-2135.
22 Schaden W, Thiele R, Kölpl C, Pusch M, Nissan A, Attinger CE, Maniscalco-
1. Hess, L.M., Jeter, J.M., Benham-Hutchins, M. & Alberts, D.S. (2008) Factors asso-
Theberge ME, Peoples GE, Elster EA, Stojadinovic A. Shock wave therapy for acute
ciated with osteonecrosis of the jaw among bisphosphonate users. American Journal
and chronic soft tissue wounds: a feasibility study. J Surg Res. 143 (2007), 1-12.
of Medicine121: 475–483, e473
23 Fukumoto Y, Ito A, Uwatoku T, Matoba T, Kishi T, Tanaka H, Takeshita A,
2 Reid, I.R. (2009) Osteonecrosis of the jaw: who gets it, and why? Bone 44: 4–10
Sunagawa K, Shimokawa H. Extracorporeal cardiac shock wave therapy ameliorates
3 Walter, C., Grotz, K.A., Kunkel, M. &Al-Nawas, B. (2007) Prevalence of bisphos-
myocardial ischemia in patients with severe coronary artery disease. Coron. Artery
phonate associated osteonecrosis of the jaw within the field of osteonecrosis.
Dis. 17 (2006),.63-70.
Supportive Care in Cancer 15: 197–202.
24 Wang CJ. An overview of shock wave therapy in musculoskeletal disorders. Chang
4 Ruggiero, S.L., Mehrotra, B., Rosenberg, T.J. & Engroff, S.L. (2004) Osteonecrosis of
Gung Med J 2003;26:220-32.
the jaws associated with the use of bisphosphonates: a review of 63 cases. Journal of
25 Haupt G, Haupt A, Ekkernkamp A, Gerety B, Chvapil M. Influence of shockwave
Oral and Maxillofacial Surgery 62: 527–534.
on fracture healing. J Urol. 1992;39:529–32.
5 Shoback, D. (2007) Update in osteoporosis and metabolic bone disorders. Journal
26 Johannes EJ, Kaulesar Sukul DM, Matura E. High-energy shockwave for treatment
of Clinical Endocrinology & Metabolism 92: 747–753.
of nonunion. An experiment on dogs. J Surg Res. 1994;57:246–52.
6 Kwon Y-D, Ohe J-Y, Kim D-Y, Chung D-J, Park Y-D. Retrospective study of two bio-
27 Wang CJ, Yang KD, Wang FS, Hsu CC, Chen HH. Shock wave treatment shows
chemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis
dose-dependent enhancement of bone mass and bone strength after fracture of the
of the jaws: can they be utilized as risk markers? Clin. Oral Impl. Res. 22, 2011;
femur. Bone. 2004;34:225–230.
100–105.
28 Wang CJ, Huang CC, Wang JW, Wong T, Yang YJ. . Long-term results of extracor-
7 Bornstein, M.M., Cionca, N. & Mombelli, A. (2009) Systemic conditions and treat-
poreal shockwave therapy and core decompression in osteonecrosis of the femoral
ments as risks for implant therapy. The International Journal of Oral & Maxillofacial
head with eight- to nine-year follow-up. Biomed J. 2012 Nov;35(6):481-5.
Implants 24 (Suppl.): 12–27.
29 Vulpiani MC, Vetrano M, Trischitta D, Scarcello L, Chizzi F, Argento G, Saraceni
8 Shirota, T., Nakamura, A., Matsui, Y., Hatori, M., Nakamura, M. & Shintani, S.
VM, Maffulli N, Ferretti A. Extracorporeal shock wave therapy in early osteonecrosis
(2009) Bisphosp